Table 4.
Factors that influence HIV/AIDS clinical trial participation, stratified by region and race
| Characteristics | Total, N = 1947a | Northeast (%) | Midwest (%) | South (%) | West (%) | Pb | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| W, n = 172 | A, n = 286 | H, n = 174 | W, n = 186 |
A, n = 255 |
H, n = 24 |
W, n = 114 |
A, n = 266 |
H, n = 86 |
W, n = 203 |
A, n = 64 |
H, n = 117 |
|||
| Facilitators to participation | ||||||||||||||
| Help fight HIV/AIDS | 1587 (82) | 152 (88) | 233 (81) | 125 (72) | 155 (83) | 219 (86) | 15 (63) | 95 (83) | 214 (80) | 58 (67) | 179 (88) | 55 (86) | 87 (74) | <.001 |
| Could receive better care | 743 (38) | 50 (29) | 112 (39) | 71 (41) | 66 (35) | 100 (39) | 8 (33) | 32 (28) | 104 (39) | 46 (53) | 71 (35) | 33 (52) | 50 (43) | 0.003 |
| Help learn more | 1053 (54) | 92 (53) | 168 (59) | 72 (41) | 103 (55) | 143 (56) | 10 (42) | 51 (45) | 157 (59) | 48 (56) | 101 (50) | 41 (64) | 67 (57) | 0.004 |
| Obtain unavailable medications | 541 (28) | 48 (28) | 75 (26) | 31 (18) | 55 (30) | 72 (28) | 5 (21) | 41 (36) | 66 (25) | 30 (35) | 67 (33) | 19 (30) | 32 (27) | 0.05 |
| More of my sex represented | 488 (25) | 47 (27) | 96 (34) | 36 (21) | 29 (16) | 69 (27) | 4 (17) | 14 (12) | 83 (31) | 27 (31) | 30 (15) | 21 (33) | 32 (27) | <.001 |
| More of my race represented | 504 (26) | 33 (19) | 103 (36) | 46 (26) | 14 (8) | 85 (33) | 4 (17) | 12 (11) | 92 (35) | 31 (36) | 12 (6) | 31 (48) | 41 (35) | <.001 |
| Provider recommended | 729 (37) | 74 (43) | 88 (31) | 52 (30) | 84 (45) | 85 (33) | 6 (25) | 55 (48) | 88 (33) | 36 (42) | 100 (49) | 20 (31) | 41 (35) | <.001 |
| Barriers to participation | ||||||||||||||
| Not “friendly” to my race | 213 (11) | 5 (3) | 45 (16) | 15 (9) | 7 (4) | 47 (18) | 5 (21) | 5 (4) | 40 (15) | 7 (8) | 10 (5) | 15 (23) | 12 (10) | <0.001 |
| Not “friendly” to my sex | 150 (8) | 5 (3) | 32 (11) | 13 (7) | 10 (5) | 24 (9) | 2 (8) | 6 (5) | 28 (11) | 5 (6) | 10 (5) | 10 (16) | 5 (4) | 0.004 |
| Not “friendly” to drug user | 153 (8) | 6 (3) | 35 (12) | 8 (5) | 8 (4) | 25 (10) | 2 (8) | 3 (3) | 33 (12) | 4 (5) | 13 (6) | 9 (14) | 7 (6) | <0.001 |
| Worry about a placebo | 315 (16) | 33 (19) | 32 (11) | 18 (10) | 47 (25) | 35 (14) | 2 (8) | 28 (25) | 22 (8) | 14 (16) | 54 (27) | 7 (11) | 23 (20) | <0.001 |
| Worry my info would be revealed | 366 (19) | 20 (12) | 64 (22) | 20 (11) | 36 (19) | 63 (25) | 9 (38) | 14 (12) | 58 (22) | 20 (23) | 29 (14) | 10 (16) | 23 (20) | <0.001 |
| Do not understand studies | 156 (8) | 5 (3) | 26 (9) | 18 (10) | 10 (5) | 20 (8) | 3 (13) | 6 (5) | 41 (15) | 8 (9) | 5 (2) | 4 (6) | 10 (9) | <0.001 |
| Do not want to be “guinea pig” | 218 (11) | 13 (8) | 39 (14) | 17 (10) | 11 (6) | 39 (15) | 2 (8) | 9 (8) | 47 (18) | 8 (9) | 10 (5) | 8 (13) | 15 (13) | <0.001 |
Only responses with statistically significant P values included in table. A, African American; AIDS, acquired immunodeficiency syndrome; H, Hispanic; HIV, human immunodeficiency virus; W, white.
a
Respondents who reported other (n = 99), mixed race (n = 23), or did not report race (n = 56) were not included in analysis.
b
P values from χ2 test of independence.